Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06805877 · ClinicalTrials.gov registry record · NA

Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing

A NA study of HIV, sponsored by Harvard Pilgrim Health Care.

Active
Registry status
NA
Development phase
16
Enrollment target
16
Study locations

NCT06805877: Active NA study of HIV, sponsored by Harvard Pilgrim Health Care.

NCT06805877 is a NA study of HIV that is active but no longer recruiting, run by Harvard Pilgrim Health Care. The registered enrollment target is 16 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06805877, a NA study of HIV, is active but no longer recruiting, sponsored by Harvard Pilgrim Health Care.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
16
Study locations

Study Summary

Scale-up of HIV preexposure prophylaxis (PrEP) is a key strategy of the U.S. initiative to end the HIV epidemic, but healthcare providers lack tools to support PrEP discussions and prescribing for patients likely to benefit. This research will evaluate whether integrating automated tools into electronic health records to help providers efficiently and equitably identify potential candidates for PrEP, discuss PrEP, and prescribe PrEP can improve PrEP initiation and persistence in safety-net community health centers. It will achieve this by conducting a stepped-wedge trial of a decision support tool with an embedded HIV prediction model to identify patients likely to benefit from PrEP. The intervention will be delivered to healthcare providers in 16 community health centers within the national OCHIN network.

Primary Outcome

Proportion of patients above the prediction model risk threshold without a recently active PrEP prescription (within the prior 6 months) or prior HIV diagnosis who are prescribed PrEP during the study period.

Conditions Studied

Interventions

  • OTHER Predictive Analytics and Clinical Decision Support

Study Locations (16)

California

  • Bay Area Community Health Liberty Clinic - Fremont
  • Lifelong East Oakland Health Center - Oakland
  • TrueCare Oceanside Family Medicine - Oceanside
  • DAP Legacy - Palm Springs
  • One Community Health Midtown Campus - Sacramento

Massachusetts

  • Lynn Community Health Center 269 Union - Lynn
  • Mattapan Community Health Center Blue Hill - Mattapan

Ohio

  • Neighborhood Family Practice Ridge Community Health Center - Cleveland
  • Signature Health Painesville - Painesville

Connecticut

  • Southwest Community Health Center 968 Fairfield Avenue - Bridgeport

Georgia

  • Mercy Care Decatur Street - Atlanta

Iowa

  • Siouxland Community Health Center Sioux City - Sioux City

Oklahoma

  • Variety Care Sequoyah - Oklahoma City

Oregon

  • Prism Belmont - Portland

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-04-21
Est. Completion 2030-07
Phase NA
Harvard Pilgrim Health Care

28 total trials

What the registry record for NCT06805877 still lists

NCT06805877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Predictive Analytics and Clinical Decision Support is the first listed.

NCT06805877 lists 16 locations in 10 states (California, Massachusetts, Ohio).

Frequently Asked Questions

What is clinical trial NCT06805877 about?

NCT06805877 is a clinical study titled "Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing". Scale-up of HIV preexposure prophylaxis (PrEP) is a key strategy of the U.S. initiative to end the HIV epidemic, but healthcare providers lack tools to support PrEP discussions and prescribing for patients likely to benefit. This research will evaluate whether integrating automated tools into electr...

What is the current status of trial NCT06805877?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2025-04-21. Estimated completion is 2030-07.

What conditions does trial NCT06805877 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT06805877?

The interventions under investigation include: Predictive Analytics and Clinical Decision Support (OTHER).

Who is sponsoring clinical trial NCT06805877?

This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06805877 being conducted?

This trial has 16 study locations across California, Connecticut, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06805877's enrollment target sits among peer trials

16 288th of 303 higher than 15 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06805877, the US trial registry maintained by the National Library of Medicine. NCT06805877 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.